α-bromoacryloyl derivative of distamycin A (PNU 151807): A new non-covalent minor groove DNA binder with antineoplastic activity

British Journal of Cancer

Volumn 80, Issue 7, 1999, Pages 991-997

  Marchini, S ^a   Ciro M ^a   Gallinari, F ^a   Geroni, C ^b   Cozzi, P ^b   D'Incalci, M ^a   Broggini, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PFIZER INC   (United States)

Author keywords

Anticancer agents; Cyclin dependent kinases; DNA binding; Minor groove binders

Indexed keywords

ACRYLAMIDE DERIVATIVE; DISTAMYCIN A; PROTEIN BAX; PROTEIN P21; PROTEIN P53; TALLIMUSTINE; TAQ POLYMERASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; COVALENT BOND; DNA ALKYLATION; DNA FOOTPRINTING; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0032903056     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690453     Document Type: Article

References (29)

1. Beccaglia P, Grimaldi KA, Hartley JA, Marchini S, Broggini M and D'Incalci M (1996) DNA adduct formation of the sequence selective cytotoxic agent tallimustine resolved at the nucleotide level in a single copy gene in mammalian cells. Br J Cancer 73: 12
2. Bonfanti M, Taverna S, D'Incalci M and Broggini M (1997) p21 WAF-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 57: 1442-1446
3. Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F and D'Incalci M (1991) Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res 51: 199-204
4. Broggini M, Coley HM, Mongelli N, Pesenti E, Wyatt MD, Hartley JA and D'Incalci M (1995) DNA sequence-specific adenine alkylation by the novel antitumor drug tallumustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 23: 81-87
5. Coley HM, Broggini M and D'Incalci M (1990) Studies of the novel distamycin compound FCE 24517 with respect to DNA interaction and sensitivity to alkylating agents. Br J Cancer 62: 506-500
6. D'Alessio R, Geroni C, Biasoli G, Pesenti E, Grandi M and Mongelli N (1994) Structure activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorganic Med Chem Lett 4: 1467-1472
7. D'Incalci M (1994) DNA-minor groove alkylators, a new class of anticancer agents. Ann Oncol 5: 877-878
8. D'Incalci M and Sessa C (1997) DNA minor groove binding ligands: a new class of anticancer agents. Exp Opin Invest Drugs 6: 875-884
9. Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA and Fiebig HH (1997) Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3: 273-279
10. Geroni C, Pesenti E, Tagliabue G, Ballinari D, Mongelli N, Broggini M, Erba E, D'Incalci M, Spreafico F and Grandi M (1993) Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies. Int J Cancer 53: 308-314
11. Ghielmini M, Bosshard G, Capolongo L, Geroni C, Pesenti E, Torri V, D'Incalci M, Cavalli F and Sessa C (1997) Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 75: 878-883
12. Hartley JA, Gibson NW, Kohn KW and Mattes WB (1986) DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer Res 46: 1943-1947
13. Hartley JA, Lown JW, Mattes WB and Kohn KW (1988) DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy. Acta Oncol 27: 503-510
14. Hertzberg RP and Dervan PB (1984) Cleavage of DNA with Methidiumpropyl-EDTA-Iron(II): reaction conditions and product analyses. Biochemistry 23: 3934-3945
15. Hurley LH, Reynolds VL, Swenson DH, Petzold GL and Scahill TA (1984) Reaction of the antitumoral antibiotic CC-1065 with DNA: structure of DNA adduct with sequence specificity. Science 226: 843-844
16. Lee M, Rhodens L, Wyatt MD, Forrow S and Hartley JA (1993) Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents. Anticancer Drug Des 8: 173-192
17. Li LH, Swenson D, Schpock S, Kuentzel S, Dayton B and Kreiger W (1982) CC-1065 (NSC-298223) a novel antitumour agent that interacts strongly with double-stranded DNA. Cancer Res 42: 999-1004
18. Li LH, Dekoning TF and Kelly RC (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904-4913
19. Marchini S, Gonzales Paz O, Ripamonti M, Geroni C, Bargiotti A, Caruso M, Todeschi S, D'Incalci M and Broggini M (1995) Sequence-specific DNA interactions by novel alkylating anthracycline derivatives. Anticancer Drug Des 10: 641-653
20. Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M and Broggini M (1998) Sequence specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des 13: (in press)
21. Mattes WB, Hartley JA and Kohn KW (1986) DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res 14: 2971-2987
22. Ponti M, Forrow SM, Souharni RL, D'Incalci M and Hartley JH (1991) Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res 19: 2929-2933
23. Reynolds VL, Molineux IJ, Kaplan DJ, Swenson DH and Hurley LH(1985) Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 24: 6228-6237
24. Sambrook J, Fritsh E and Maniatis T (1989) Molecolar Cloning: A Laboratory Manual, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press
25. Sessa C, Pagani O, Zurlo MG, Jong DE, Hoffmann C, Lassus M, Marrari P, Strolin, Benedetti M and Cavalli F (1994) Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 5: 901-907
26. Sun D and Hurley LH (1992) Effect of the (+)-CC-1065-(N3-adenine) DNA adduct on in vitro DNA synthesis mediated by Escherichia coli DNA polymerase. Biochemistry 31: 2822-2829
27. Tishler RB, Lamppu DM, Park S and Price BD (1995) Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55: 6021-6025
28. Vikhanskaya F, Erba E, D'Incalci M and Broggini M (1994) Introduction of wild-type p53 in human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 22: 1012-1017
29. Vikhanskaya F, Vignati S, Beccaglia P, Ottoboni C, Russo P, D'Incalci M and Broggini M (1998) Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 241: 96-101